Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Other Non-Current Assets (2016 - 2025)

Editas Medicine (EDIT) has disclosed Other Non-Current Assets for 11 consecutive years, with $3.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets fell 43.38% to $3.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.0 million, a 43.38% decrease, with the full-year FY2024 number at $5.2 million, down 39.18% from a year prior.
  • Other Non-Current Assets was $3.0 million for Q3 2025 at Editas Medicine, down from $4.2 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $9.5 million in Q1 2024 to a low of $3.0 million in Q3 2025.
  • A 5-year average of $6.3 million and a median of $6.8 million in 2023 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: soared 179.72% in 2021, then plummeted 55.75% in 2025.
  • Editas Medicine's Other Non-Current Assets stood at $6.8 million in 2021, then dropped by 22.87% to $5.3 million in 2022, then surged by 63.49% to $8.6 million in 2023, then plummeted by 39.18% to $5.2 million in 2024, then plummeted by 42.75% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Other Non-Current Assets are $3.0 million (Q3 2025), $4.2 million (Q2 2025), and $4.2 million (Q1 2025).